Skip to main content
Fig. 3 | Journal of Hematology & Oncology

Fig. 3

From: Response and progression-free survival according to planned treatment duration in patients with relapsed multiple myeloma treated with carfilzomib, lenalidomide, and dexamethasone (KRd) versus lenalidomide and dexamethasone (Rd) in the phase III ASPIRE study

Fig. 3

PFS in KRd patients: ≥CR responders versus <CR responders by select subgroups in ASPIRE. a High-risk cytogenetics. b Prior bortezomib therapy. c One prior line of treatment. d Two or more prior lines of treatment. ≥CR, complete response or better; <CR, less than complete response; KRd, carfilzomib, lenalidomide and dexamethasone; PFS, progression-free survival

Back to article page

Journal of Hematology & Oncology

ISSN: 1756-8722

Contact us